Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Factor VII Stories

2010-06-28 07:00:00

WAYNE, N.J., June 28 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today launched FactorTrack(TM), the first customizable mobile application for people with hemophilia A. FactorTrack is a free, personal and interactive mobile application that helps make it easier to track and record hemophilia factor VIII infusions. FactorTrack captures dosing history, frequency and locations of bleeds. It allows people with hemophilia A to customize their infusion schedule based on their...

2010-03-31 11:36:30

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today. And the very treatments that can help can also put patients' lives at risk. The standard treatment is infusion with an expensively produced protein that helps the blood to clot. But in some patients the immune system fights the therapy, and in a subset of those, it sets off an allergic reaction that can result in death. Now researchers at...

2009-11-16 13:40:52

When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research from North Carolina State University shows that much more needs to be done to help get existing treatment to hemophilia patients in the developing world, and that the current lack of treatment there is costing lives. "This research illustrates international disparities in...

2009-08-26 08:45:00

LACHEN, Switzerland and HOBOKEN, N.J., Aug. 26 /PRNewswire/ -- Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with...

2009-08-07 07:30:00

WAYNE, N.J., Aug. 7 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a 3000 IU (international unit) vial size of Kogenate(R) FS, antihemophilic factor (recombinant). The new vial size offers greater convenience for patients with hemophilia A who require a higher dose. The 3000 IU vial may eliminate the need for combining smaller vials and may allow some patients to achieve more precise dosing. It is available...

2009-07-14 06:30:00

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical...

2009-07-13 07:00:00

BOSTON, July 13 /PRNewswire/ -- New data pooled from four large, "real world" post-marketing surveillance studies showed that sucrose-formulated recombinant factor VIII (rFVIII-FS) reduced bleeding and provided data regarding adverse events in more than 950 patients with mild-to-severe hemophilia A. Additionally, rates of inhibitor formation were reported in both previously treated and previously untreated patients. The data were presented at the XXII Congress of the International Society on...

2009-07-09 11:00:00

WAYNE, N.J., July 9 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals launched the BayCuff(TM) self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their caregivers. The centerpiece of the program is an adjustable cuff worn on the hand or arm that allows patients to practice the technique of self-injection without actually infusing themselves and helps caregivers learn to...

2009-04-17 07:30:00

BERKELEY, Calif., April 17 /PRNewswire/ -- In recognition of the 20th anniversary of World Hemophilia Day, Bayer HealthCare reaffirmed its commitment to the global hemophilia community by pledging euro 250,000 to the World Federation of Hemophilia (WFH). To mark this milestone, Bayer employees around the world will engage in activities to support the mission of this annual event - to increase awareness of and promote support for the needs of people living with hemophilia and other bleeding...

2009-02-12 07:30:00

IB1001, an Intravenous Recombinant Factor IX (rFIX) Product for the Treatment of Hemophilia B LAGUNA NIGUEL, Calif., Feb. 12 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., today announced the initiation of a Phase 1 clinical trial of IB1001, an intravenous (IV) recombinant Factor IX (rFIX) product for control and prevention of hemorrhagic episodes in patients with hemophilia B. It is estimated that the market for therapies to treat this disorder is in excess of $600 million. The...